Pretzsch Charlotte M., et al.
Translational psychiatry, 2019
Abstract
Autism spectrum disorder (ASD) is a high cost neurodevelopmental condition; and there are currently no effective pharmacological treatments for its core symptoms. This has led some families and researchers to trial alternative remedies - including the non-intoxicating Cannabis sativa-derived compound cannabidivarin (CBDV). However, how CBDV affects the human brain is unknown. Previous (pre)clinical evidence suggests that CBDV may modulate brain excitatory-inhibitory systems, which are implicated in ASD. Hence, our main aim was to test, for the first time, if CBDV shifts glutamate and/or GABA metabolites - markers of the brain's primary excitatory and inhibitory system - in both the 'typical' and autistic brain. Our subsidiary aim was to determine whether, within ASD, brain responsivity to CBDV challenge is related to baseline biological phenotype. We tested this using a repeated-measures, double-blind, randomized-order, cross-over design. We used magnetic resonance spectroscopy (MRS) to compare glutamate (Glx = glutamate + glutamine) and GABA + (GABA + macromolecules) levels following placebo (baseline) and 600 mg CBDV in 34 healthy men with (n = 17) and without (n = 17) ASD. Data acquisition from regions previously reliably linked to ASD (dorsomedial prefrontal cortex, DMPFC; left basal ganglia, BG) commenced 2 h (peak plasma levels) after placebo/CBDV administration. Where CBDV significantly shifted metabolite levels, we examined the relationship of this change with baseline metabolite levels. Test sessions were at least 13 days apart to ensure CBDV wash-out. CBDV significantly increased Glx in the BG of both groups. However, this impact was not uniform across individuals. In the ASD group, and not in the typically developing controls, the 'shift' in Glx correlated negatively with baseline Glx concentration. In contrast, CBDV had no significant impact on Glx in the DMPFC, or on GABA+ in either voxel in either group. Our findings suggest that, as measured by MRS, CBDV modulates the glutamate-GABA system in the BG but not in frontal regions. Moreover, there is individual variation in response depending on baseline biochemistry. Future studies should examine the effect of CBDV on behaviour and if the response to an acute dose of CBDV could predict a potential clinical treatment response in ASD.
Conflict of interest statement
The authors declare that they have no conflict of interest.| PMID: | 31748505 |
|---|---|
| PMCID (Free PMC Article): | PMC6868232 |
| DOI: | 10.1038/s41398-019-0654-8 |
| Category: | Brain / Mental Clarity |
The best supplements with Cannabis Sativa or Cannabidivarin in Brain / Mental Clarity category:
- Absolute Nature - Full Spectrum 1000 mg CBG & CBD Oil Drops / Tincture – 30ml - Our top-quality beautifully golden full-spectrum CBG & CBD oil tincture contains not only a high amount of CBG & CBD, but other naturally-occurring cannabinoids, terpenes, flavonoids, plant proteins, mineral, vitamins, essential fatty acids and other beneficial compounds from the cannabis/hemp plant, providing the best possible benefits without the high. It contains among others: Cannabidivarin.
Articles similar to "Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy."
- The significance of Cannabis Sativa for Brain / Mental Clarity: Cannabis Essential Oil: A Preliminary Study for the Evaluation of the Brain Effects. (We examined the effects of essential oil from legal (THC <0...)
- The impact of Cannabidivarin on Brain / Mental Clarity: Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. (Epilepsy is the most common neurological disorder, with over 50 million people worldwide affected...)